In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs Prices Control Order,

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 3186] ubZ fnYyh] eaxyokj] vxLr 14] 2018@Jko.k 23] 1940 No. 3186] NEW DELHI, TUESDAY, AUGUST 14, 2018/SHRAVANA 23, 1940 jlk;u vkSj moZjd ea=ky; ¼vkS"k/k foHkkx½ ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ vkns’k ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3982¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh dz- vuqlwfpr fofufeZfr izcyrk bdkbZ fofuekZrk vkSj foi.ku [kqnjk ewY; la- dk uke@czkaM dk daiuh ¼#-½ uke (1) (2) (3) (4) (5) (6) 1. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu xksyh esa% 1 xksyh eSllZ I;ksj ,aM D;ksj 11.70 DyksfiMksxzsy xksyh jkstqokLVkfVu dSfY’k;e ds cjkcj gsYFkds;j izk- fy-@eSllZ jkstqokLVkfVu 10 fexzk-] ;uhesM VsDuksykWtht fy- DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- 2. ,eksDlhflfyu $ izR;sd 5 fefy- iqufuZfeZr fuyacu esa% 1 fefy- eSllZ lsVsd esfMds;j 3.01 Dykoqyfud ,flM ,eksDlhflfyu VªhgkbMªsV vkbZih ds izk- fy-@eSllZ gsxMs ,aM lLisa’ku cjkcj ,EyksDlhflfyu 400 fexzk-] gsxMs QkekZL;wfVdYl iksVsf’k;e DykoqyusV fMyqVsM vkbZih ,y,yih ds cjkcj Dykoqyfud ,flM 75 fexzk- ikykVscqy lLisa’ku D;w,l 4770 GI/2018 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] dyj vizksoM ch dyj ;wtM ou ,Eikmyh dksuVsu LVfjyh okVj QkWj batsD’ku vkbih 30 fefy- 3. vksYeslkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ lk;uksdse 9.30 ,EyksfMikbu $ vksYeslkVZu esMksDlksfey vkbZih 20 QkekZL;wfVdYl fy- DyksjFkkfyMksu xksyh @eSllZ tqosuVl fexzk-] gsYFkds;j fy- ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- vkSj DyksjFkkfyMksu vkbZih 12-5 fexzk- 4. vksYeslkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ lk;uksdse 16.19 ,EyksfMikbu $ vksYeslkVZu esMksDlksfey vkbZih 40 QkekZL;wfVdYl fy- DyksjFkkfyMksu xksyh @eSllZ tqosuVl fexzk-] gsYFkds;j fy- ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- vkSj DyksjFkkfyMksu vkbZih 12-5 fexzk- 5. felksizksLVksy xksyh izR;sd vfyfir xksyh esa% 1 xksyh eSllZ lk;uksdse 4.37 felksizksLVksy vkbZih 25 ,elhth QkekZL;wfVdYl fy- ¼felksizksLVksy 1 izfr’kr fMlij’ku½ @eSllZ tk;Ml gsYFkds;j fy- 6. felksizksLVksy xksyh izR;sd vfyfir xksyh esa% 1 xksyh eSllZ lk;uksdse 56.93 felksizksLVksy vkbZih 600 ,elhth QkekZL;wfVdYl fy- ¼felksizksLVksy 1 izfr’kr fMlij’ku½ @eSllZ tk;Ml gsYFkds;j fy- 7. Q~ywukjhtkbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 5.39 izksizkuksyksy xksyh Q~ywukjhtkbu fMgkbMksDyksjkbM chih QkekZL;wfVdYl izk- fy- @eSllZ ,CcksV gsYFkds;j ds cjkcj Q~ywukjhtkbu 5 fexzk-] izk- fy- izksizkuksyksy gkbMªksDyksjkbM vkbZih 40 fexzk-¼lLVsaM fjfyt esa½ 8. Q~ywukjhtkbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 7.20 izksizkuksyksy xksyh Q~ywukjhtkbu fMgkbMksDyksjkbM chih QkekZL;wfVdYl izk- fy- @eSllZ ,CcksV gsYFkds;j ds cjkcj Q~ywukjhtkbu 10 fexzk-] izk- fy- izksizkuksyksy gkbMªksDyksjkbM vkbZih 40 fexzk-¼lLVsaM fjfyt esa½ 9. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ ,dEl MªXl ,aM 13.10 DyksfiMksxzsy dSIlwy jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl izk- fy- ¼jkstV lhoh½ jkstqokLVkfVu 10 fexzk- ¼izR;sd fQYe @eSllZ MkW- jsM~Mht fyfir xksyh esa½] yscksjsVjht fy- DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼izR;sd fQYe fyfir xksyh esa½ 10. lsfQDlhe $ izR;sd 5 fefy- iqufuZfeZr fuyacu esa% 1 fefy- eSllZ VwouVh QLV 2.17 Dykoqfyfud ,flM lsfQDlhe VªhgkbMªsV vkbZih ds cjkcj lsapwjh QkekZL;wfVdYl lLisa’ku lsfQDlhe 50 fexzk-] izk- fy- @eSllZ iksVsf’k;e DykoqyusV fMyqVsM vkbZih XysuekdZ QkekZL;wfVdYl ds cjkcj Dykoqyfud ,flM 31-25 fy- fexzk- ,DlhisaVl ou ,EikWy ¼,Q,Q,l½ vkWQ LVsfjy okVj QkWj batsD’ku vkbZih 30 fefy- 11. jkosizktksy $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ foaMykl ck;ksVsd 8.46 MkseisfjMksu dSIlwy jkosizktksy lksfM;e vkbZih 40 fy-@eSllZ dSfMyk QkekZL;wfVdYl fy- ¼jsMfM’k czkmu ,uVsfjd fyfir iSysVl½] MkseisfjMksu vkbZih 30 fexzk- ¼vkWjsat dyMZ lLVsaM fjfyt iSysVl½ 12. ,lhDyksQsud $ izR;sd vfyfir xksyh esa% 1 xksyh eSllZ cusZV 3.27 iSjkflVkeksy xksyh ,lhDyksQsud vkbZih 100 fexzk-] QkekZL;wfVdYl izk- fy- ¼DyksusV½¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 iSjkflVkeksy vkbZih 325 fexzk- 13. ,YcsuMktksy $ izR;sd vfyfir fMlijlscy xksyh esa% 1 xksyh eSllZ cusZV 17.48 bojesLVhu xksyh ,YcsuMktksy vkbZih 400 fexzk- QkekZL;wfVdYl izk- fy- ¼chbZ,u$½ bojesLVhu vkbZih 6 fexzk- 14. flYuhfMikbu $ izR;sd fQYe fyfir foys;MZ xksyh 1 xksyh eSllZ ,dEl MªXl ,aM 7.346 esVksizksyksy xksyh esa% QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ flYuhfMikbu vkbZih 10 fexzk-] fy- esVksizksyksy lqlkbusV vkbZih ds cjkcj esVksizksyksy VkjVªsV 50 fexzk- ¼,DlVsaM fjfyt QkWeZ esa½ 15. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ foaMykl ck;ksVsd 8.234 DyksfiMksxzsy dSIlwy ,VksjokLVkfVu dSfY’k;e vkbZih ds izk- fy-@eSllZ tqfcysaV ¼tqfcdksM lhoh 10½ ykbQ lkbaflt fy- cjkcj ,VksjokLVkfVu 10 fexzk- ¼fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir xksyh esa½ 16. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ foaMykl ck;ksVsd 13.30 DyksfiMksxzsy dSIlwy ,VksjokLVkfVu dSfY’k;e vkbZih ds izk- fy-@eSllZ tqfcysaV ¼tqfcdksM lhoh 20½ ykbQ lkbaflt fy- cjkcj ,VksjokLVkfVu 20 fexzk- ¼fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir xksyh esa½ 17. VsyfelkVZu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ gsVsjks yscl izk- 7.92 DyksjFkkyhMksu xksyh VsyfelkVZu vkbZih 40 fexzk-] fy-@eSllZ tqfcysaV ¼Vsyfetqc lh,p 40½ ykbQ lkbaflt fy- DyksjFkkyhMksu vkbZih 12-50 fexzk- xksyh 18. VsyfelkVZu $ izR;sd vfyfir fcys;j xksyh esa% 1 xksyh eSllZ gsVsjks yscl izk- 13.82 DyksjFkkyhMksu xksyh VsyfelkVZu vkbZih 80 fexzk-] fy-@eSllZ tqfcysaV ¼Vsyfetqc lh,p 80½ ykbQ lkbaflt fy- DyksjFkkyhMksu vkbZih 12-50 fexzk- xksyh 19. iSjkflVkeksy $ izR;sd vfyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 3.06 QsuhysQzhu $ dSQhu iSjkflVkeksy vkbZih 500 fexzk-] QkekZL;wfVdYl fy-@ $ fMQsugkbMªkekbu eSllZ ,CcksV gsYFkds;j QsuhysQzhu gkbMªksDyksjkbM vkbZih 5 xksyh izk- fy- fexzk-] dSQhu ¼,ugkbMªkst½ vkbZih 30 fexzk-] fMQsugkbMªkekbu gkbMªksDyksjkbM vkbZih 25 fexzk- 20 fXyDyktkbM $ izR;sd vfyfir xksyh esa% 1 xksyh eSllZ esfMQkslZ 8.38 esVQksfeZu xksyh fXyDyktkbM vkbZih 60 fexzk- gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy- ¼,DlVsaM fjfyt QkWeZ esa½] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼,DlVsaM fjfyt QkWeZ esa½ 21. XyhesihjkbM $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ esfMQkslZ 3.77 esVQksfeZu xksyh XyhesihjkbM vkbZih 0-5 fexzk-] gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy- esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk-¼lLVsaM fjfyt QkWeZ½ 22. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 8.394 DyksfiMksxzsy dSIlwy ,VksjokLVkfVu dSfY’k;e vkbZih ds QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ cjkcj ,VksjokLVkfVu 10 fexzk- fy- ¼iSysVl esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 754 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] fexzk- ¼iSysVl esa½ 23. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 10.596 DyksfiMksxzsy dSIlwy ,VksjokLVkfVu dSfY’k;e vkbZih ds QkekZL;wfVdYl fy-@ eSllZ esudkbaM QkekZ cjkcj ,VksjokLVkfVu 20 fexzk- fy- ¼iSysVl esa½] DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½ 24. lksQksLcqohj $ izR;sd fQYe vfyfir xksyh esa% 28 xksyh eSllZ ukVdks QkekZ fy-@ 15481.86 osyirkLohj xksyh lksQksLcqohj 400 fexzk-] eSllZ ,CcksV bafM;k fy- osyirkLohj 100 fexzk- 25. fMlkbDyksekbu izR;sd vfyfir xksyh% 1 xksyh eSllZ dksuVsLV 0.85 gkbMªksDyksjkbM xksyh fMlkbDyksekbu gkbMªksDyksjkbM dSfedYl fy- vkbZih 20 fexzk- 26. VªkLVqtqec batsD’ku izR;sd dkWEch fdV esa% izfr iSd eSllZ fjyk;al ykbQ 18400.89 ,½ izR;sd y;ksfQfytsM ok;y esa lkbalst izk- fy-@eSllZ VªkLVqtqec vkbZ,p,l 150 fexzk-] yqfiu fy- ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 20 ;w,lih 0-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy- 27. VªkLVqtqec batsD’ku izR;sd dkWEch fdV esa% izfr iSd eSllZ MkW- jsM~Mht 18125.00 ,½ izR;sd y;ksfQfytsM ok;y esa yscksjsVjht fy- VªkLVqtqec vkbZ,p,l 150 fexzk-] ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 20 ;w,lih 0-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy- 28. cqMslksukbM jsliYl izR;sd 2 fefy- fjliysl esa% 2 fefy- eSllZ lu 17.59 0-5 fexzk-@2fefy- cqMslksukbM vkbZih 0-5 fexzk- iSd QkekZL;wfVdYl esfMds;j ¼lLisa’ku QkWj fy-@eSllZ lu QkekZ uscqykbts’ku½ yscksjsVjht fy- 29. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 11.53 ,fLifju $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ DyksfiMksxzsy dSIlwy jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] eSllZ esMksQkekZ ¼lqyVkfVu xksYM½ ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 30. Qsjl ,LdkscsZV $ izR;sd fefy- MªksIl esa% 1 fefy- eSllZ ,isDl yscksjsVjht 3.58 Qksfyd ,flM MªksIl Qsjl ,LdkscsZV ds cjkcj bysesuVy izk- fy- ¼VªhQj $ ,DlVh½ vk;ju 10 fexzk-] Qksfyd ,flM vkbZih 100 ,elhth¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 31. VªkLVqtqeo batsD’ku izR;sd dkWEch fdV esa% izfr iSd eSllZ fjyk;al ykbQ 18125.00 ,½ izR;sd y;ksfQfytsM ok;y esa lkbalst izk- fy-@eSllZ VªkLVqtqec vkbZ,p,l 150 fexzk-] vkjihth ykbQ lkbalst ,] ,YQk Vªsgykst fMgkbMªsV 136-2 fy- fexzk-] ,y&fglVhMkbu ,plh,y 3-36 fexzk-] ,y&fglVhMkbu 2-16 fexzk-] ikWyhlkscsZV 200-6 fexzk-] ch½ izR;sd LVsjkby MCY;w,QvkbZ ok;y esa LVsjkby okVj QkWj batsD’ku vkbZih 10 fefy- 32. QksjeksVsjksy $ izR;sd 2 fefy- fjliysl esa% 2 fefy- eSllZ lu 35.04 cqMslksukbM lLisa’ku QksjeksVsjksy QqekjsV fMgkbMªsV vkbZih iSd QkekZL;wfVdYl esfMds;j ¼QkseVkbM 0-5½ fy-@eSllZ lu QkekZ ds cjkcj QksjeksVsjksy QqekjsV 20 yscksjsVjht fy- ,elhth] cqMslksukbM vkbZih 0-5 fexzk- 33. QksjeksVsjksy $ izR;sd 2 fefy- fjliysl esa% 2 fefy- eSllZ lu 40.96 cqMslksukbM lLisa’ku QksjeksVsjksy QqekjsV fMgkbMªsV vkbZih iSd QkekZL;wfVdYl esfMds;j ¼QkseVkbM 1½ fy-@eSllZ lu QkekZ ds cjkcj QksjeksVsjksy QqekjsV 20 yscksjsVjht fy- ,elhth] cqMslksukbM vkbZih 1 fexzk- 34. fjdksefcuaV g~;qeu izR;sd ih,Q,l esa% izfr iSd eSllZ Hkkjr lsje ,aM 1294.64 dksfj;ksfud fjdksefcuaV g~;qeu dksfj;ksfud oSDlhu fy- xksukMksVªksfiu QkWj xksukMksVªksfiu QkWj batsD’ku 6500 batsD’ku vkbZ;w 35. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 13.76 ,EyksfMikbu $ VsyfelkVZu 80 fexzk- QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼VªhVsylkj 80 ,p,l½ DyksjFkkyhMksu 12-5 fexzk- 36. vksYeslkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 9.25 ,EyksfMikbu $ vksYeslkVZu esMksDlksfey 20 fexzk-] QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼Vªh;ksVsylkj 20 DyksjFkkyhMksu 12-5 fexzk- ,p,l½ 37. vksYeslkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 16.70 ,EyksfMikbu $ vksYeslkVZu esMksDlksfey 40 fexzk-] QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼Vªh;ksVsylkj 40 DyksjFkkfyMksu 12-5 fexzk- ,p,l½ 38. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 8.35 ,EyksfMikbu $ VsyfelkVZu 40 fexzk-] QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼VªhVsylkj 40 ½ DyksjFkkyhMksu 6-25 fexzk- 39. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 9.37 ,EyksfMikbu $ VsyfelkVZu 40 fexzk-] QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼VªhVsylkj 40 ,p,l½ DyksjFkkyhMksu 12-50 fexzk- 40. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ thds,e U;w 14.47 ,EyksfMikbu $ VsyfelkVZu 80 fexzk-] QkekZ@ eSllZ ;wuhdse DyksjFkkyhMksu xksyh yscksjsVjht fy- ,EyksfMikbu 5 fexzk-] ¼VªhVsylkj 80½ DyksjFkkyhMksu 6-25 fexzk-6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 41. MkWDlhlkbfDyu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ csusV 4.96 ySfDVd ,flM MkWDlhlkbfDyu gkbDysV vkbZih ds QkekZL;wfVdYl fy- cSflyl dSIlwy cjkcj MkWDlhlkbfDyu 100 fexzk-] ySfDVd ,flM cSflyl 5 fcfy;u Liksjsl 42. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ l;kuksdse 11.53 DyksfiMksxzsy $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy- ,fLifju dSIlwy jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] @eSllZ ,ifjdk ,fLifju vkbZih 75 fexzk- ¼vkarfjd gsYFkds;j izk- fy- fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 43. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ l;kuksdse 17.88 DyksfiMksxzsy $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy- ,fLifju dSIlwy jkstqokLVkfVu 20 fexzk- ¼iSysVl esa½] @eSllZ ,ifjdk ,fLifju vkbZih 75 fexzk- ¼vkarfjd gsYFkds;j izk- fy- fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 44. esekuVkbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ fFk;ksu 9.93 Mksusisttkby xksyh esekuVkbu gkbMªksDyksjkbM ;w,lih 5 QkekZL;wfVdYl fy- fexzk-] @eSllZ beD;ksj Mksusisttkby gkbMªksDyksjkbM vkbZih QkekZL;wfVdYl fy- 5 fexzk- 45. esekuVkbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ fFk;ksu 12.56 Mksusisttkby xksyh esekuVkbu gkbMªksDyksjkbM ;w,lih QkekZL;wfVdYl fy-@ 10 fexzk-] eSllZ beD;ksj Mksusisttkby gkbMªksDyksjkbM vkbZih QkekZL;wfVdYl fy- 5 fexzk- 46. flYuhfMikbu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 7.77 VsyfelkVZu xksyh VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl fy-@ flYuhfMikbu 10 fexzk- eSllZ ,CcksV gsYFkds;j izk- fy- 47. gk;kslkbu izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ tk;Ml gsYFkds;j 8.99 cqVkbczksekbM $ gk;kslkbu cqVkbczksekbM vkbZih 10 fy- esQsukfed ,flM fexzk-] xksyh esQsukfed ,flM xksyh vkbZih 250 fexzk- 48. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 11.53 ,fLifju $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ DyksfiMksxzsy dSIlwy jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] eSllZ fliyk fy- ¼jkslqfyi xksYM 10½ ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 49. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 17.88 ,fLifju $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ DyksfiMksxzsy dSIlwy jkstqokLVkfVu 20 fexzk- ¼iSysVl esa½] eSllZ fliyk fy- ¼jkslqfyi xksYM 20½ ,fLifju vkbZih 75 fexzk- ¼vkarfjd fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 50. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 11.53 ,fLifju $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ DyksfiMksxzsy dSIlwy jkstqokLVkfVu 10 fexzk- ¼iSysVl esa½] eSllZ VkWjsZaV ¼;wuhLVkj xksYM ,fLifju vkbZih 75 fexzk- ¼vkarfjd QkekZL;wfVdYl fy- 10@75½ fyfir iSysVl esa½¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 51. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 17.88 ,fLifju $ jkstqokLVkfVu dSfY’k;e ds cjkcj QkekZL;wfVdYl fy-@ DyksfiMksxzsy dSIlwy jkstqokLVkfVu 20 fexzk- ¼iSysVl esa½] eSllZ VkWjsZaV ¼;wuhLVkj xksYM ,fLifju vkbZih 75 fexzk- ¼vkarfjd QkekZL;wfVdYl fy- 20@75½ fyfir iSysVl esa½ DyksfiMksxzsy ckblYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-¼iSysVl esa½ 52. XyhesfijkbM $ izR;sd vfyfir fcys;MZ xksyh esa% 1 xksyh eSllZ foaMykl ck;ksVsd 3.77 esVQksfeZu ,plh,y XyhesihjkbM vkbZih 0-5 fexzk-] izk- fy-@eSllZ XysuekdZ xksyh QkekZL;wfVdYl fy- esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk-¼izksykWxM fjfyt QkWeZ½ 53. VsyfelkVZu $ izR;sd lLVsu fjfyt xksyh esa% 1 xksyh eSllZ ck;ksyVl 7.58 esVksizksyksy xksyh VsyfelkVZu 40 fexzk-] QkekZL;wfVdYl izk- fy- ¼Vsyfeizkbe chVk 25½ esVksizksyksy 25 fexzk- @ eSllZ izhel jsfefMt izk- fy- 54. VsyfelkVZu $ izR;sd lLVsu fjfyt xksyh esa% 1 xksyh eSllZ ck;ksyVl 9.10 esVksizksyksy xksyh VsyfelkVZu 40 fexzk-] QkekZL;wfVdYl izk- fy- ¼Vsyfeizkbe chVk 50½ esVksizksyksy 50 fexzk- @ eSllZ izhel jsfefMt izk- fy- 55. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 5.22 DyksfiMksxzsy $ ,VksjokLVkfVu dSfY’k;e vkbZih ds QkekZL;wfVdYl fy-@ ,fLifju dSIlwy eSllZ tk;Ml gsYFkds;j cjkcj ,VksjokLVkfVu 20 fexzk- fy- ¼iSysVl esa½] ,aM ,fLifju vkbZih 75 fexzk- ¼vkarfjd eSllZ VªhLVkj QkWeqZys’ku fyfir iSysVl esa½ izk- fy-@eSllZ tk;Ml DyksfiMksxzsy ckblYQsV vkbZih ds gsYFkds;j fy- cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½ 56. ,VksjokLVkfVu $ izR;sd gkMZ tsykVkbu dSIlwy esa% 1 dSIlwy eSllZ lk;uksdse 3.86 DyksfiMksxzsy $ ,VksjokLVkfVu dSfY’k;e vkbZih ds QkekZL;wfVdYl fy- ,fLifju dSIlwy @eSllZ tk;Ml cjkcj ,VksjokLVkfVu 10 fexzk- gsYFkds;j fy- ¼iSysVl esa½] ,aM ,fLifju vkbZih 75 fexzk- ¼vkarfjd eSllZ VªhLVkj QkWeqZys’ku fyfir iSysVl esa½ izk- fy-@eSllZ tk;Ml DyksfiMksxzsy ckblYQsV vkbZih ds gsYFkds;j fy- cjkcj DyksfiMksxzsy 75 fexzk- ¼iSysVl esa½ 57. esfFkydksckykfeu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllz ,svkWu QkWeqZys’ku 5.45 esVQksfeZu xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih 500 izk- fy-@eSllZ ;wlhoh ¼XykbdksesV 500 izk- fy- fexzk-¼,lvkj QkWeZ½ ,elh½ esfFkydksckykfeu ts-ih- 750 ,elhth 58. esfFkydksckykfeu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllz ,svkWu QkWeqZys’ku 7.97 esVQksfeZu xksyh esVQksfeZu gkbMªksDyksjkbM vkbZih izk- fy-@eSllZ ;wlhoh ¼fxykbdksesV 1000 izk- fy- 1000 fexzk-¼,lvkj QkWeZ½ ,elh½ esfFkydksckykfeu ts-ih- 750 ,elhth 59. Qsjl ,LdkscsZV $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ QkekZQsczhdksu 6.22 Qksfyd ,flM $ Qsjl ,LdkscsZV ds cjkcj bysesuVy ftad lYQsV xksyh vk;ju 100 fexzk-] ¼izksfodksu&Qh½ Qksfyd ,flM vkbZih 1-5 fexzk-] ftad lYQsV eksuksgkbMªsV ds cjkcj bysesuVy ftad 22-5 fexzk-8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 60. Qsjl ,LdkscsZV $ izR;sd fefy- esa*% 1 fefy- eSllZ QkekZQsczhdksu 0.744 Qksfyd ,flM Qsjl ,LdkscsZV ds cjkcj bysesuVy lLisa’ku vk;ju 30 fexzk-+] ¼izksfodksu&Qh½ Qksfyd ,flM vkbZih 500 ,elhth 61. ,lhyksQsud $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ fcaMykl ck;ksVsd 3.34 iSjkflVkeksy xksyh ,dsyksQsud vkbZih 100 fexzk-] izk- fy-@eSllZ fou ¼fousl½½ iSjkflVkeksy vkbZih 235 fexzk- esMds;j izk- fy- 62. fMDyksQsud lksfM;e izR;sd fefy- batsD’ku esa% 1 fefy- eSllz csusV 20.00 batsD’ku fMDyksQsud lksfM;e vkbZih 75 iSd QkekZL;wfVdYl fy- fexzk-] okWVj QkWj batsD’ku vkbZih D;w,l 63. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 8.62 ,EyksfMikbu $ VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ bidk ¼lhVhMh&Ve 6- cjkcj ,EyksfMikbu 5 fexzk-] yscksjsVjht fy- 25@40@5½ DyksjFkkyhMksu vkbZih 6-25 fexzk- 64. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 8.75 ,EyksfMikbu $ VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ bidk ¼lhVhMh&Ve 12- cjkcj ,EyksfMikbu 5 fexzk-] yscksjsVjht fy- 5@40@5½ DyksjFkkyhMksu vkbZih 12-50 fexzk- 65. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 14.40 ,EyksfMikbu $ VsyfelkVZu vkbZih 80 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ bidk ¼lhVhMh&Ve 6- cjkcj ,EyksfMikbu 5 fexzk-] yscksjsVjht fy- 25@80@5½ DyksjFkkyhMksu vkbZih 6-25 fexzk- 66. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 14.00 ,EyksfMikbu $ VsyfelkVZu vkbZih 80 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ bidk ¼lhVhMh&Ve 12- cjkcj ,EyksfMikbu 5 fexzk-] yscksjsVjht fy- 5@80@5½ DyksjFkkyhMksu vkbZih 12-50 fexzk- 67. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 14.12 ,EyksfMikbu $ VsyfelkVZu vkbZih 80 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ ,fjLVks ¼Vsyokl 3 Mh lhVh cjkcj ,EyksfMikbu 5 fexzk-] QkekZL;wfVdYl izk- fy- 40½ DyksjFkkyhMksu vkbZih 12-50 fexzk- 68. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ ,dEl MªXl ,aM 8.91 ,EyksfMikbu $ VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh ,EyksfMikbu fclkbysV vkbZih ds @eSllZ ,fjLVks ¼Vsyokl 3 Mh lhVh cjkcj ,EyksfMikbu 5 fexzk-] QkekZL;wfVdYl izk- fy- 40½ DyksjFkkyhMksu vkbZih 12-50 fexzk- 69. VsyfelkVZu $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ lk;uksdse 10.16 flYuhfMikbu $ VsyfelkVZu vkbZih 40 fexzk-] QkekZL;wfVdYl fy- DyksjFkkyhMksu xksyh flYuhfMikbu fclkbysV vkbZih ds @eSllZ bidk ¼lhVhMh&Vhlh 6-25½ cjkcj ,EyksfMikbu 5 fexzk-] yscksjsVjht fy- DyksjFkkyhMksu vkbZih 6-25 fexzk- 70. ihbZth ,y & izR;sd 5 fefy- ok;y batsD’ku esa% 5 fefy- eSllZ fojpkso ck;ksVsd 38730.74 ,sLiSjtkbusl batsD’ku ihbZth ,y & ,sLiSjtkbusl batsD’ku @ok;y izk- fy-@eSllZ dSfMyk 750 vkbZ;w@fefy- QkekZL;wfVdYl fy- 71. ihbZth ,y & izR;sd 5 fefy- ok;y batsD’ku esa% 5 fefy- eSllZ dSfMyk gsYFkds;j 38730.74 ,sLiSjtkbusl batsD’ku ihbZth ,y & ,sLiSjtkbusl batsD’ku @ok;y fy- 750 vkbZ;w@fefy- 72. Qsjl ,LdkscsZV $ izR;sd fQYe fyfir xksyh esa% 1 xksyh eSllZ fr:ifr esfMds;j 9.44 Qksfyd ,flM $ Qsjl ,LdkscsZV ds cjkcj bysesuVy fy-@eSllZ dSfMyk l;kuksdksckyfeu $ vk;ju 100 fexzk-] gsYFkds;j fy- ikbjhMkWfDlu $ Qksfyd ,flM vkbZih 1-5 fexzk-] dksysDylhQsjksy xksyh l;kuksdksckyfeu ¼foVkfeu ch12½ vkbZih 7-5 ,elhth] ikbjhMkWfDlu gkbMªksDyksjkbM¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9 ¼foVkfeu ch6½ vkbZih 1-5 fexzk-] dksysDylhQsjksy ¼foVkfeu Mh3½ vkbZih 1000 vkbZ;w uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA [dka- la-@191@59/2018@,Q@Qk- la- 8¼59½@2018@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (National Pharmaceutical Pricing Authority) ORDER New Delhi, the 13th August, 2018 S.O. 3982(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Brand Marketing Company Price Name (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin + Each film coated tablet contains: 1 Tablet M/s Pure and Cure 11.70 Clopidogrel Tablet Rosuvastatin Calcium IP eq. to Healthcare Pvt. Ltd. / Rosuvastatin 10mg, M/s Unimed Technologies Ltd. Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg. 2. Amoxicillin + Each 5ml of reconstituted suspension 1 ML M/s Saitech Medicare 3.01 Clavulanic Acid contains: Pvt. Ltd. Suspension Amoxicillin Trihydrate IP eq. to / M/s Hegde & Hegde Amoxyiillin 400mg, Pharmaceutical LLP Potassium Clavulante Diluted IP eq. to Clavulanic Acid 57mg In a Palatable suspension q.s. Color Approved colour used B One Ampoule Contain Sterile Water for Injection IP 30ml 3. Olmesartan Each film coated tablet contains: 1 Tablet M/s Synokem 9.30 +Amlodipine + Olmesartan Medoxomil IP 20mg, Pharmaceuticals Limited Chlorthalidone Tablet / M/s Zuventus Amlodipine Besylate IP eq. to Healthcare Limited Amlodipine 5mg & Chlorthalidone IP 12.5mg 4. Olmesartan Each film coated tablet contains: 1 Tablet M/s Synokem 16.19 +Amlodipine + Olmesartan Medoxomil IP 40mg, Pharmaceuticals / M/s Chlorthalidone Tablet Zuventus Healthcare Amlodipine Besylate IP eq. to Limited Amlodipine 5mg & Chlorthalidone IP 12.5mg 5. Misoprostol Tablet Each uncoated tablets contains: 1 Tablet M/s Synokem 4.37 Misoprostol IP 25mcg (As Pharmaceuticals Limited Misoprostol 1% Dispersion) / M/s Zydus Healthcare Limited 6. Misoprostol Tablet Each uncoated tablets contains: 1 Tablet M/s Synokem 56.93 Misoprostol IP 600mcg (As Pharmaceuticals Limited Misoprostol 1% Dispersion) / M/s Zydus Healthcare Limited 7. Flunarizine + Each uncoated bilayered tablet 1 Tablet M/s Akums Drugs and 5.39 Propranolol tablet contains: Pharmaceuticals Pvt. Flunarizine Dihydrochloride BP eq. Ltd. / M/s Abbott to Flunarizine 5mg, Healthcare Pvt. Ltd. Propranolol Hydrochloride IP 40mg (As Sustained Release) 8. Flunarizine + Each uncoated bilayered tablet 1 Tablet M/s Akums Drugs and 7.20 Propranolol tablet contains: Pharmaceuticals Pvt. Flunarizine Dihydrochloride BP eq. Ltd. / M/s Abbott to Flunarizine 10mg, Healthcare Pvt. Ltd. Propranolol Hydrochloride IP 40mg (As Sustained Release) 9. Rosuvastatin + Each hard Gelatin capsule contains: 1 M/s Akums Drugs and 13.10 Clopidogrel capsule Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Pvt.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11 (Rozat CV) Rosuvastatin 10mg (As film coated Ltd. / M/s Dr. Reddy’s form tablet), Laboratories Limited Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet form) 10. Cefixime + Each 5ml of reconstituted 1 ML M/s Twenty First 2.17 Clavulanic Acid Suspension contains: Century Pharmaceuticals suspension Cefixime Trihydrate IP eq. to Pvt. Ltd. / M/s Cefixime 50mg, Glenmark Pharmaceuticals Ltd. Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 31.25mg Excipients. One Ampoule (FFS) of Sterile water for Injection IP 30ml 11. Rabeprazole + Each hard gelatine capsule contains: 1 M/s Windlas Biotech 8.46 Domperidone Capsule Rabeprazole Sodium IP 40mg (As Capsule Ltd. / M/s Cadila Reddish brown enteric coated Pharmaceuticals Limited pellets) Domperidone IP 30mg (As orange coloured sustained released pallets) 12. Aceclofenac + Each Uncoated tablet contains: 1 Tablet M/s Burnet 3.27 Paracetamol Tablet Aceclofenac IP 100mg, Pharmaceuticals Pvt. (CLONET ) Ltd. Paracetamol IP 325mg 13. Albendazole + Each uncoated dispersible tablet 1 Tablet M/s Burnet 17.48 Ivermectin Tablet contains: Pharmaceuticals Pvt. (BEN +) Albendazole IP 400mg, Ltd. Ivermectin IP 6mg 14. Cilnidipine + Each film coated bilayered tablet 1 Tablet M/s Akums Drugs and 7.346 Metoprolol tablet contains: Pharmaceuicals Ltd. / Cilnidipine IP 10mg, M/s Mankind Pharma Ltd. Metoprolol Succinate IP eq. to Metoprolol Tartrate 50mg (In extended release form) 15. Atorvastatin + Each hard gelatine capsule contains: 1 M/s Windlas Biotech 8.234 Clopidogrel capsule Atorvastatin Calcium IP eq. to Capsule Pvt. Ltd. / M/s Jubilant (Jubicoad CV 10) Atorvastatin 10mg (As film coated Life Sicences Limited tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 16. Atorvastatin + Each hard gelatine capsule contains: 1 M/s Windlas Biotech 13.30 Clopidogrel capsule Atorvastatin Calcium IP eq. to Capsule Pvt. Ltd. / M/s Jubilant (Jubicoad CV 20) Atorvastatin 20mg (As film coated Life Sicences Limited tablets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 17. Telmisartan + Each Uncoated bilayer tablet 1 Tablet M/s Hetero Labs Pvt. 7.92 Chlorthalidone tablet contains: Ltd. / M/s Jubilant Life (Telmijub CH 40) Telmisartan IP 40mg, Sciences Limited Chlorthalidone IP 12.50mg Tablets12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 18. Telmisartan + Each Uncoated bilayer tablet 1 Tablet M/s Hetero Labs Pvt. 13.82 Chlorthalidone tablet contains: Ltd. / M/s Jubilant Life (Telmijub CH 80) Telmisartan IP 80mg + Sciences Limited Chlorthalidone IP 12.50mg Tablet 19. Paracetamol + Each uncoated tablet contains: 1 Tablet M/s Akums Drugs & 3.06 Phenylephrine + Paracetamol IP 500mg Pharmaceuticals Ltd. / Caffeine + M/s Abbott Healthcare Phenylephrine Hydrochloride IP Diphenhydramine Pvt. Ltd. 5mg, Tablet Caffeine (Anhydrous) IP 30mg, Diphenhydramine Hydrochloride IP 25mg 20 Gliclazide + Each uncoated tablet contains: 1 Tablet M/s Mediforce 8.38 Metformin tablet Gliclazide IP 60mg (in extended Healthcare Pvt. Ltd. / release form) M/s Mankind Pharma Limited Metformin Hydrochloride IP 500mg (in extended release form) 21. Glimepiride + Each uncoated bilayered tablet 1 Tablet M/s Mediforce 3.77 Metformin tablet contains: Healthcare Pvt. Ltd. / Glimepiride IP 0.5mg M/s Mankind Pharma Limited Metformin Hydrochloride IP 500mg (in sustained release form) 22. Atorvastatin + Each hard gelatine capsule contains: 1 M/s Synokem 8.394 Clopidogrel Capsule Atorvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd. / Atorvastatin 10mg (As pellets) M/s Mankind Pharma Limited Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) 23. Atorvastatin + Each hard gelatine capsule contains: 1 M/s Synokem 10.596 Clopidogrel Capsule Atorvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd. / Atorvastatin 20mg (As pellets) M/s Mankind Pharma Limited Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) 24. Sofosbuvir + Each film coated tablet contains: 28’s M/s Natco Pharma 15481.86 Velpatasvir tablet Sofosbuvir 400mg, Tablets Limited / M/s Abbott India Limited Velpatasvir 100mg 25. Dicyclomine Each uncoated tablet contains: 1 Tablet M/s Kontest Chemicals 0.85 Hydrochloride Tablet Dicyclomine Hydrochloride IP 20 Ltd. mg 26. Trastuzumab Each combi kit contains Per Pack M/s Reliance 18400.89 Injection A) Each Lyophilized vial containing Lifesciences Pvt. Ltd. / M/s Lupin Ltd, Trastuzumab IHS 150 mg, A,α trehalose dihydrate 136.2 mg, L-Histidine HCL 3.36 mg, L-Histidine 2.16 mg, Polysorbate 20 0.6 mg B) Each sterile WFI vial containing Sterile water for injection IP 10 ml 27. Trastuzumab Each combi kit contains Per Pack Dr. Reddy’s 18125.00 Injection A) Each Lyophilized vial containing Laboratories Ltd. Trastuzumab IHS 150 mg,¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13 A,α trehalose dihydrate 136.2 mg, L-Histidine HCL 3.36 mg, L-Histidine 2.16 mg, Polysorbate 20 0.6 mg B) Each sterile WFI vial containing Sterile water for injection IP 10 ml 28. Budesonide respules Each 2 ml respules contains: 2 ml M/s Sun Pharmaceutical 17.59 0.5mg/2ml Budesonide IP 0.5 mg Pack Medicare Ltd. / M/s Sun (suspension for Pharma Laboratories nebulisation) Ltd. 29. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 11.53 Aspirin + Rosuvastatin Calcium eq to Capsule Pharmaceuticals Ltd. / Clopidogrel Capsule Rosuvastatin 10mg (as pellets) M/s Medopharm (Sultatin Gold) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq to Clopidogrel 75 mg (as pellets) 30. Ferrous Ascorbate + Each ml drops contains: 1 ML M/s Apex laboratories 3.58 Folic acids drops Ferrous Ascorbate eq to elemental Pvt. Ltd. (Trifer – XT) iron 10mg Folic Acid IP 100mcg 31. Trastuzumab Each combi kit contains Per Pack M/s Reliance Life 18125.00 Injection A) Each Lyophilized vial containing Sciences Pvt. Ltd. / M/s RPG Life Sciences Ltd. Trastuzumab IHS 150 mg, A,α trehalose dihydrate 136.2 mg, L-Histidine HCL 3.36 mg, L-Histidine 2.16 mg, Polysorbate 20 0.6 mg B) Each sterile WFI vial containing Sterile water for injection IP 10 ml 32. Formoterol + Each 2 ml respules contains: 2 ML M/s Sun Pharmaceutical 35.04 Budesonide Formoterol Fumarate Dihydrate IP Pack Medicare Ltd. / M/s Sun Suspension eq. to Formoterol Fumarate 20 mcg Pharma Laboratories Ltd (Fomtide 0.5) Budesonide IP 0.5 mg 33. Formoterol + Each 2 ml respules contains: 2 ML M/s Sun Pharmaceutical 40.96 Budesonide Formoterol Fumarate Dihydrate IP Pack Medicare Ltd. / M/s Sun Suspension eq to Formoterol Fumarate 20mcg Pharma Laboratories Ltd (Fomtide 1) Budesonide IP 1 mg 34. Recombinant Human Each PFS containing Each M/s Bharat Serums and 1294.64 Chorionic Recombinant Human Chorionic Pack Vaccines Ltd. Gonadotropin for Gonadotropin for Injection 6500IU Injection 35. Telmisartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 13.76 Amlodipine + Telmisartan IP 80mg M/s Unichem Chlorthalidone Laboratories Limited. Amlodipine Besylate IP eq. to Tablet Amlodipine 5mg (Tritelsar 80 HS) Chlorthalidone IP 12.50mg 36. Olmesartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 9.25 Amlodipine + Olmesartan Medoxomil IP 20mg M/s Unichem Chlorthalidone14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Tablet Amlodipine Besylate IP eq. to Laboratories Limited. (Triolsar 20 HS) Amlodipine 5mg Chlorthalidone IP 12.50mg 37. Olmesartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 16.70 Amlodipine + Olmesartan Medoxomil IP 40mg M/s Unichem Chlorthalidone Laboratories Limited. Amlodipine Besylate IP eq. to Tablet Amlodipine 5mg (Triolsar 40 HS) Chlorthalidone IP12.50mg 38. Telmisartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 8.35 Amlodipine + Telmisartan IP 40mg M/s Unichem Chlorthalidone Laboratories Limited. Amlodipine Besylate IP eq. to Tablet Amlodipine 5mg (Tritelsar 40) Chlorthalidone IP 6.25mg 39. Telmisartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 9.37 Amlodipine + Telmisartan IP 40mg M/s Unichem Chlorthalidone Laboratories Limited. Amlodipine Besylate IP eq. to Tablet Amlodipine 5mg (Tritelsar 40 HS) Chlorthalidone IP 12.50mg 40. Telmisartan + Each film coated tablet contains: 1 Tablet M/s GKM New Pharma / 14.47 Amlodipine + Telmisartan IP 80mg M/s Unichem Chlorthalidone Laboratories Limited. Amlodipine Besylate IP eq. to Tablet Amlodipine 5mg (Tritelsar 80) Chlorthalidone IP 6.25mg 41. Doxycycline + Lactic Each hard gelatin capsules 1 M/s Bennet 4.96 acid bacillus Capsules containing Capsule Pharmaceuticals Ltd. Doxycycline Hyclate IP eq to Doxycycline 100 mg Lactic Acid Bacillus 5 billion spores 42. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 11.53 Clopidogrel + Aspirin Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Capsules Rosuvastatin 10mg (as pellets) M/s Aprica Healthcare Pvt. Ltd. Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets) 43. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 17.88 Clopidogrel + Aspirin Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Capsules Rosuvastatin 20mg (as pellets) M/s Aprica Healthcare Pvt. Ltd. Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg (as pellets) 44. Memantine + Each film coated tablet containing 1 Tablet M/s Theon 9.93 Donepezil Tablet Memantine Hydrochloride USP 5mg Pharmaceuticals Ltd. / M/s Emcure Donepezil Hydrochloride IP 5mg Pharmaceuticals Ltd. 45. Memantine + Each film coated tablet containing 1 Tablet M/s Theon 12.56 Donepezil Tablet Memantine Hydrochloride USP Pharmaceuticals Ltd. / 10mg M/s Emcure Pharmaceuticals Ltd. Donepezil Hydrochloride IP 5mg¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15 46. Cilnidipine + Each film coated tablet containing 1 Tablet M/s Akums Drugs & 7.77 Telmisartan Tablet Telmisartan IP 40mg Pharmaceuticals Ltd. / M/s Abbott Healthcare Cilnidipine 10 mg Pvt. Ltd. 47. Hyoscine Each film coated tablet containing 1 Tablet M/s Zydus Healthcare 8.99 Butybromide + Hyoscine Butybromide IP 10 mg Ltd. Mefenamic Acid Mefenamic Acid Tablet IP 250mg Tablet 48. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 11.53 Aspirin + Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Clopidogrel Capsule Rosuvastatin 10mg (as pellets) M/s Cipla Ltd. (Rosulip Gold 10) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP e. to Clopidogrel 75 mg (as pellets) 49. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 17.88 Aspirin + Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Clopidogrel Capsule Rosuvastatin 20mg (as pellets) M/s Cipla Ltd. (Rosulip Gold 20) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP e. to Clopidogrel 75 mg (as pellets) 50. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 11.53 Aspirin + Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Clopidogrel Capsule Rosuvastatin 10mg (as pellets) M/s Torrent Pharmaceuticals Ltd (Unistar Gold 10/75) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP e. to Clopidogrel 75 mg (as pellets) 51. Rosuvastatin + Each hard gelatin capsule containing 1 M/s Synokem 17.88 Aspirin + Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. / Clopidogrel Capsule Rosuvastatin 20mg (as pellets) M/s Torrent Pharmaceuticals Ltd (Unistar Gold 20/75) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel Bisulphate IP e. to Clopidogrel 75 mg (as pellets) 52. Glimepiride + Each uncoated bilayered tablet 1 Tablet M/s Windlas Biotech 3.77 Metformin HCL containing Pvt. Ltd. / M/s Glenmark tablet Glimepiride IP 0.5 mg Pharmaceuticals Ltd. Metformin Hydrochloride IP 500 mg (as prolonged released form) 53. Telmisartan + Each sustain release tablet containing 1 Tablet M/s Bioaltus 7.58 Metoprolol Tablet Telmisartan 40mg Pharmaceuticals Pvt. (Telmiprime Beta 25) Ltd. / M/s Primus Metoprolol 25 mg Remedies Pvt. Ltd. 54. Telmisartan + Each sustain release tablet containing 1 Tablet M/s Bioaltus 9.10 Metoprolol Tablet Telmisartan 40mg Pharmaceuticals Pvt. (Telmiprime Beta 50) Ltd. / M/s Primus Metoprolol 50 mg Remedies Pvt. Ltd. 55. Atorvastatin + Each hard gelatin capsule containing 1 M/s Synokem 5.22 Clopidogrel + Aspirin Atorvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd. / Capsule Atorvastatin 20 mg (as pellets) M/s Zydus Healthcare16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Aspirin IP 75 mg (as enteric coated Ltd. and pellets) M/s Tristar Formulations Clopidogrel Bisulphate IP eq. to Pvt. Ltd. / M/s Zydus Clopidogrel 75 mg (as pellets) Healthcare Ltd. 56. Atorvastatin + Each hard gelatin capsule containing 1 M/s Synokem 3.86 Clopidogrel + Aspirin Atorvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd. / Capsule Atorvastatin 10 mg (as pellets) M/s Zydus Healthcare Ltd. and Aspirin IP 75 mg (as enteric coated pellets) M/s Tristar Formulations Pvt. Ltd. / M/s Zydus Clopidogrel Bisulphate IP eq. to Healthcare Ltd. Clopidogrel 75 mg (as pellets) 57. Methylcobalamin + Each film coated tablet contains: 1 Tablet M/s Aeon Formulations 5.45 Metformin Tablet Metformin Hydrochloride IP 500mg Pvt. Ltd. / M/s USV Pvt. (Glycomet 500 MC) (As SR form) Ltd. Methylcobalamin J.P. 750mcg 58. Methylcobalamin + Each film coated tablet contains: 1 Tablet M/s Aeon Formulations 7.97 Metformin Tablet Metformin Hydrochloride IP Pvt. Ltd. / M/s USV Pvt. (Glycomet 1000 MC) 1000mg (As SR form) Ltd. Methylcobalamin J.P. 750mcg 59. Ferrous Ascorbate + Each film coated tablet contains: 1 Tablet M/s Pharmafabrikon 6.22 Folic Acid + Zinc Ferrous Ascorbate eq. to elemental Sulphate Tablet iron 100mg (Provikon-Fe) Folic Acid IP 1.5mg Zinc Sulphate Monohydrate eq. to elemental Zinc 22.5mg 60. Ferrous Ascorbate + Each 5ml contains: 1 ML M/s Pharmafabrikon 0.744 Folic Acid Ferrous Ascorbate eq. to elemental Suspension iron 30mg (Provikon-Fe) Folic Acid IP 550mcg 61. Acelofenac + Each film coated tablet contains: 1 Tablet M/s Windlas Biotech 3.34 Paracetamol Tablet Acelofenac IP 100 mg Pvt. Ltd. / M/s Win (Winace) Paracetamol IP 325 mg Medicare Pvt. Ltd. 62. Diclofenac Sodium Each ml injection contains: 1 ML M/s Bennet 20.00 Injection Diclofenac Sodium IP 75 mg Pack Pharmaceuticals Ltd. Water for Injection Ip QS 63. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 8.62 Amlodipine + Telmisartan IP 40 mg pharmaceuticals Ltd. / M/s Ipca Laboratories Chlorthalidone Tablet Amlodipine Besylate IP eq. to Ltd. (CTD-Tam 6.25/40/5) Amlodipine 5 mg Chlorthalidone IP 6.25 mg 64. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 8.75 Amlodipine + Telmisartan IP 40 mg pharmaceuticals Ltd. / M/s Ipca Laboratories Chlorthalidone Tablet Amlodipine Besylate IP eq. to Ltd. (CTD-Tam 12.5/40/5) Amlodipine 5 mg Chlorthalidone IP 12.5 mg 65. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 14.40 Amlodipine + Telmisartan IP 80 mg pharmaceuticals Ltd. / M/s Ipca Laboratories Chlorthalidone Tablet Amlodipine Besylate IP eq. to Ltd. (CTD-Tam 6.25/80/5) Amlodipine 5 mg Chlorthalidone IP 6.25 mg¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17 66. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 14.00 Amlodipine + Telmisartan IP 80 mg pharmaceuticals Ltd. / M/s Ipca Laboratories Chlorthalidone Tablet Amlodipine Besylate IP eq. to Ltd. (CTD-Tam 12.5/80/5) Amlodipine 5 mg Chlorthalidone IP 12.5 mg 67. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 14.12 Amlodipine + Telmisartan IP 80 mg pharmaceuticals Ltd. / M/s Aristo Chlorthalidone Tablet Amlodipine Besylate IP eq. to Pharmaceuticals Pvt. (Telvas 3D CT 80) Amlodipine 5 mg Ltd. Chlorthalidone IP 12.5 mg 68. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Akum Drugs & 8.91 Amlodipine + Telmisartan IP 40 mg pharmaceuticals Ltd. / M/s Aristo Chlorthalidone Tablet Amlodipine Besylate IP eq. to Pharmaceuticals Pvt. (Telvas 3D CT 40) Amlodipine 5 mg Ltd. Chlorthalidone IP 12.5 mg 69. Telmisartan + Each film coated tablet contains: 1 Tablet M/s Synokem 10.16 Cilnidipine + Telmisartan IP 40 mg Pharmaceuticals Ltd. / M/s Ipca Laboratories Chlorthalidone Tablet Cilnidipine IP 10 mg Ltd. (CTD-TC 6.25) Chlorthalidone IP 6.25 mg 70. PEG L-Asparginase Each 5 ml vial injection contains: 5 M/s Virchow Biotech 38730.74 Injection PEG L-Asparginase Injection 750 ML/Vial Pvt. Ltd. / M/s Cadila IU/ml Pharmaceuticals Ltd 71. PEG L-Asparginase Each 5 ml vial injection contains: 5 M/s Cadila Healthcare 38730.74 Injection PEG L-Asparginase Injection 750 ML/Vial Ltd. IU/ml 72. Ferrous Ascorbate + Each film coated tablet containing 1 Tablet M/s Tirupati Medicare 9.44 Folic Acid + Ferrous Ascorbate eq. to elemental Ltd. / M/s Cadila Cyanocobalamin + iron 100mg Healthcare Ltd. Pyridoxine + Folic Acid IP 1.5 mg Cholecalciferol tablet Cyanocobalamin (Vitamin B12) IP 7.5mcg Pyridoxine Hydrochloride (Vitamin B6) IP 1.5 mg Cholecalciferol (Vitamin D3) IP 1000IU Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the18 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/191/59/2018/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director आदशे ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3983¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS% lkj.kh dz- vuqlwfpr fofufeZfr [kqjkd :i ,oa bdkbZ vf/kdre iqufoZyksdu vkns’k la- ekStwnk dk- vk- la- ,oa la- dk uke izcyrk dher ¼#-½ ,oa rkjh[k rkjh[k (1) (2) (3) (4) (5) (6) (7) 1. ,fe;ksMksjsu batsD’ku 50 1 fefy- 20.94 31015/18/2016- 1461(v) fnukad fexzk-@fefy- ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 34) 29.05.2018 2. ,EQksVsfjflu ch batsD’ku ds izfr iSd 3844.83 31015/18/2018- 1461(v) fnukad fyfiM@fyikslksey fy, ikmMj 50 ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 fexzk- dh rkjh[k (Ø-la- 52) 08.06.2018 3. jsuhfVfMu vksjy fybZD;wM 1 fefy- 0.68 31015/78/2016- 1461(v) fnukad 75 fexzk-@5 ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 fefy- dh rkjh[k (Ø-la- 703) 08.06.2018¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 19 4. eSVªksfuMktksy xksyh 200 1 xksyh 0.43 31015/78/2016- 1461(v) fnukad fexzk- ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 553) 08.06.2018 5. eSVªksfuMktksy xksyh 400 1 xksyh 0.80 31015/78/2016- 1461(v) fnukad fexzk- ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 554) 08.06.2018 6. lsoksQ~ywjsu bugsys'ku 1 fefy- 28.07 31015/95/2017- 1461(v) fnukad ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 734) 29.05.2018 vkSj 31015/103/2017- ihvkbZ-I ewY; fu/kkZj.k dh rkjh[k 22.06.2018 7. vkWDlkfyIysfVu batsD’ku 50 izfr iSd 2439.44 31015/105/2017- 1461(v) fnukad fexzk- ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 597) 22.06.2018 8. DyksVªhektksy Øhe 1% 1 xzke 2.73 31015/19/2017- 1461(v) fnukad ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 206) 10.01.2018 9. MsDlVªku&40 batsD’ku 10% 1 fefy- 0.80 31015/03/2017- 1461(v) fnukad ihvkbZ-I ewY; fu/kkZj.k 02.04.2018 dh rkjh[k (Ø-la- 246) 24.08.2018 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA [dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 13th August, 2018 S.O. 3983(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. Name of the Dosage form Unit Ceiling Review Order Existing SO number No. Scheduled & Strength Price number and date and date Formulation (Rs.) (1) (2) (3) (4) (5) (6) (7) 1. Amiodarone Injection 1 ML 20.94 31015/18/2016-PI.I 1461(E) dated 50mg/ml dated 29.5.2018 02.04.2018 (at Sl. No. 34) 2. Amphotericin B Powder for Each Pack 3844.83 31015/18/2018- 1461(E) dated Lipid/Liposomal Injection 50mg Pricing dated 02.04.2018 08.6.2018 (at Sl. No. 52) 3. Ranitidine Oral liquid 1 ML 0.68 31015/78/2016-PI.I 1461(E) dated 75mg/5ml dated 08.6.2018 02.04.2018 (at Sl. No. 703)¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 21 4. Metronidazole Tablet 200mg 1 Tablet 0.43 31015/78/2016-PI.I 1461(E) dated dated 08.6.2018 02.04.2018 (at Sl. No. 553) 5. Metronidazole Tablet 400mg 1 Tablet 0.80 31015/78/2016-PI.I 1461(E) dated dated 08.6.2018 02.04.2018 (at Sl. No. 554) 6. Sevoflurane Inhalation 1 ML 28.07 31015/95/2017- 1461(E) dated Pricing dated 02.04.2018 29.5.2018 (at Sl. No. 734) & 31015/103/2017- Pricing dated 22.6.2018 7. Oxaliplatin Injection Each Pack 2439.44 31015/105/2017- 1461(E) dated 50mg. Pricing dated 02.04.2018 22.6.2018 (at Sl. No. 597) 8. Clotrimazole Cream 1% 1 GM 2.73 31015/19/2017- 1461(E) dated Pricing dated 02.04.2018 10.01.2018 (at Sl. No. 206) 9. Dextran-40 Injection 10% 1 ML 0.80 31015/3/2017-Pricing 1461(E) dated dated 24.08.2017 02.04.2018 (at Sl. No. 246) Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.22 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/191/59/2018/F /F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director vkns’k ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3984¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼8½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh Ø- fofufeZfr dk uke [kqjkd :i ,oa izcyrk bdkbZ [kqnjk iqufoZyksdu vkns’k ekStwnk dk- vk- fofuekZrk vkSj la- ewY; la- ,oa rkjh[k la- ,oa rkjh[k foi.ku daiuh (1) (2) (3) (4) (5) (6) (7) (8) 1. VsyfelkVZu $ izR;sd fQYe fyfir 1 xksyh 7.74 31015/07/2018- 3915(v) eSllZ lu QkekZ ,EyksfMikbu xksyh xksyh esa% VsyfelkVZu ewY; fu/kkZj.k dh fnukad yscksjsVfjt fy- ¼fVxkVsy ,,e 40½ vkbZih 40 fexzk-] fnukad 29.05.2018 18.12.2017 ,EyksfMikbu fclkbysV (Ø-la- 39) vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- 2. VsyfelkVZu$ izR;sd vfyfir xksyh 1 xksyh 8.36 31015/07/2018- 3915(v) eSllZ lu QkekZ gkbMªksDyksjksfFk;ktkbM esa% ewY; fu/kkZj.k dh fnukad yscksjsVfjt fy- xksyh ¼fVxkVsy ,p 40½ VsyfelkVZu vkbZih 40 fnukad 29.05.2018 18.12.2017 fexzk-] (Ø-la- 55) gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk- 3. VsyfelkVZu $ izR;sd vfyfir xksyh 1 xksyh 13.3 31015/07/2018- 3915(v) eSllZ lu QkekZ gkbMªksDyksjksfFk;ktkbM esa% 5 ewY; fu/kkZj.k dh fnukad yscksjsVfjt fy- xksyh ¼fVxkVsy ,p 80½ VsyfelkVZu vkbZih 80 fnukad 29.05.2018 18.12.2017 fexzk-] (Ø-la- 56) gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk- 4. VsyfelkVZu $ izR;sd vfyfir xksyh 1 xksyh 8.33 31015/07/ 3915(v) eSllZ lu QkekZ ,EyksfMikbu xksyh esa% 2018- fnukad yscksjsVfjt fy- ¼fVxkVsy ,,e,p 40½ VsyfelkVZu vkbZih 40 ewY; fu/kkZj.k dh 18.12.2017 fexzk-] fnukad 29.05.2018 (Ø-la- 57) ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 23 5. VsyfelkVZu $ izR;sd vfyfir xksyh 1 xksyh 13.0 31015/07/2018- 3915(v) eSllZ lu QkekZ ,EyksfMikbu xksyh esa% 6 ewY; fu/kkZj.k dh fnukad yscksjsVfjt fy- ¼fVxkVsy ,,ep 80½ VsyfelkVZu vkbZih 80 fnukad 29.05.2018 18.12.2017 fexzk-] (Ø-la- 58) ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk- 6. jkstqokLVkfVu $ izR;sd gkMZ tsykVkbu 1 dSIlwy 11.7 31015/20/2018- 544(v) eSllZ ,fLifju DyksfiMksxzsy dSIlwy esa% 0 ewY; fu/kkZj.k dh fnukad lk;uksdse dSIlwy ¼jkstqdksj xksYM jkstqokLVkfVu dSfY’k;e fnukad 08.06.2018 06.02.2018 QkekZL;wfVdYl 10½ vkbZih ds cjkcj fy-@eSllZ (Ø-la- 26) jkstqokLVkfVu 10 fexzk- VkWjsaV ¼isysVl es½] QkekZL;wfVdYl fy- ,fLifju vkbZih 75 fexzk- ¼xkLVªks jsfllVsaV isySVl esa½] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk- ¼isysVl esa½ 7. lsfQDlhe $ izR;sd fQYe fyfir 1 xksyh 10.5 31015/17/2018- 270(E) eSllZ Fksvksu vksQ~yksDlklhu xksyh xksyh esa% 9 ewY; fu/kkZj.k dh dated QkekZL;wfVdYl ¼LVkulsQ&vks Iyl½ lsfQDlhe VªhgkbMªsV ds fnukad 22.06.2018 16.01.2018 fy-@eSllZ lu cjkcj lsfQDlhe QkekZL;wfVdYl (at Sl. No. ,ugkbMªkst vkbZih 200 baMLVªh;y fy- 27) fexzk-] vksQ~yksDlklhu vkbZih 200 fexzk- 8. VªkbZilhu $ czksesysu $ izR;sd vkarfjd fyfir 1 xksyh 14.1 31015/17/2018- 270(E) eSllZ :VkslkbM $ xksyh esa% 0 ewY; fu/kkZj.k dh dated lk;uksdse fMDyksQsud xksyh VªkbZilhu chih 48 fnukad 22.06.2018 16.01.2018 QkekZL;wfVdYl ¼oksfyVªk butks½ fexzk-] fy-@eSllZ lu (at Sl. No. QkekZL;wfVdYl Czksesysu 90 fexzk-] 28) baMLVªht fy- :VkslkbM VªhgkbMªsV chih 100 fexzk- fMDyksQsud lksfM;e vkbZih 50 fexzk- 9. isjkflVkeksy $ izR;sd vfyfir xksyh 1 xksyh 1.78 31015/19/2018- 544(v) eSllZ ,dEl MkbZlkbDyksekbu xksyh esa% ewY; fu/kkZj.k dh fnukad MªXl ,aM ¼islheksy Likl½ isjkflVkeksy vkbZih fnukad 22.06.2018 06.02.2018 QkekZL;wfVdYl 500 fexzk-] fy-@eSllZ (Ø-la- 1) vkbZihlh, MkbZlkbDyksekbu yscksjsVfjt fy- gkbMªksDyksjkbM vkbZih 20 fexzk- 10. isjkflVkeksy $ dSQhu izR;sd fQYe fyfir 1 xksyh 2.36 31015/19/2018- 544(v) eSllZ xksyh ¼islheksy ,fDVo½ xksyh esa% ewY; fu/kkZj.k dh fnukad vkbZihlh, isjkflVkeksy vkbZih fnukad 22.06.2018 06.02.2018 yscksjsVfjt fy- 650 fexzk-] (Ø-la- 6) dSQhu ,ugkbMªkst vkbZih 50 fexzk- 11. VsyfelkVZu $ izR;sd fQYe fyfir 1 xksyh 9.00 31015/22/2018- 544(v) eSllZ lu QkekZ ,EyksfMikbu $ xksyh esa% ewY; fu/kkZj.k dh fnukad yscksjsVfjt fy- DyksjFkkfyMksu xksyh VsyfelkVZu vkbZih 40 fnukad 22.06.2018 06.02.2018 ¼fVxkVsy ,lh,p 40½ fexzk-] (Ø-la- 17) ,EyksfMikbu fclkbysV vkbZih ds cjkcj ,EyksfMikbu 5 fexzk- gkbMªksDyksjksfFk;ktkbM vkbZih 12-5 fexzk-24 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mi;qZDr tsusjfd@leku lajpuk okyk dksbZ Hkh czkaM@ lacaf/kr fofufeZfr;ksa dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA [dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 13th August, 2018 S.O. 3984(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as specified in the corresponding entries in columns (3), (4) and (8) thereof; TABLE Sl. Name of the Dosage form & Unit Retail Review Order Existing SO Manufacturer No. Formulation Strength Price number and number & & Marketing (Rs.) date date Company respectively (1) (2) (3) (4) (5) (6) (7) (8) 1. Telmisartan + Each film coated 1 Tablet 7.74 31015/7/2018- 3915(E) dated M/s Sun Pharma Amlodipine Tablet tablet contains: Pricing dated 18.12.2017 Laboratories (Tigatel AM 40) Telmisartan IP 40mg, 29.5.2018 (at Sl. No. 39) Limited Amlodipine Besylate IP eq. to Amlodipine 5mg 2. Telmisartan + Each uncoated tablet 1 Tablet 8.36 31015/7/2018- 3915(E) dated M/s Sun Pharma Hydrochlorothiazide contains: Pricing dated 18.12.2017 Laboratories Tablet Telmisartan IP 40mg, 29.5.2018 (at Sl. No. 55) Limited¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 25 (Tigatel H 40) Hydrochlorothiazide IP 12.5mg 3. Telmisartan + Each uncoated tablet 1 Tablet 13.35 31015/7/2018- 3915(E) dated M/s Sun Pharma Hydrochlorothiazide contains: Pricing dated 18.12.2017 Laboratories Tablet Telmisartan IP 80mg, 29.5.2018 (at Sl. No. 56) Limited (Tigatel H 80) Hydrochlorothiazide IP 12.5mg 4. Telmisartan + Each uncoated tablet 1 Tablet 8.33 31015/7/2018- 3915(E) dated M/s Sun Pharma Amlodipine Tablet contains: Pricing dated 18.12.2017 Laboratories (Tigatel AMH 40) Telmisartan IP 40mg, 29.5.2018 (at Sl. No. 57) Limited Amlodipine Besylate IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg 5. Telmisartan + Each uncoated tablet 1 Tablet 13.06 31015/7/2018- 3915(E) dated M/s Sun Pharma Amlodipine Tablet contains: Pricing dated 18.12.2017 Laboratories (Tigatel AMH 80) Telmisartan IP 80mg, 29.5.2018 (at Sl. No. 58) Limited Amlodipine Besylate IP Eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg 6. Rosuvastatin + Each Hard Gelatine 1 11.70 31015/20/2018- 544(E) dated M/s Synokem Aspirin + Capsule contains: Capsule Pricing dated 06.02.2018 Pharmaceuticals Clopidogrel Capsule Rosuvastatin Calcium 08.6.2018 (at Sl. No. 26) Limited / M/s (Rozucor Gold 10) IP eq. to Torrent Rosuvastation 10mg Pharmaceuticals (As pellets), Limited Aspirin IP 75mg (As Gastro - resistant pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets) 7. Cefixime + Each film coated 1 Tablet 10.59 31015/17/2018- 270(E) dated M/s Theon Ofloxacin Tablet tablet contains: Pricing dated 16.01.2018 Pharmaceuticals (Stancef-O Plus) C e f i x i me Trihydrate 22.6.2018 (at Sl. No. 27) Limited a/ M/s eq. to Cefixime Sun Anhydrous IP 200mg, Pharmaceutical Industrial Ofloxacin IP 200mg Limited 8. Trypsin + Bromelain Each enteric coated 1 Tablet 14.10 31015/17/2018- 270(E) dated M/s Synokem + tablet contains: Pricing dated 16.01.2018 Pharmaceuticals Rutoside + Trypsin BP 48mg, 22.6.2018 (at Sl. No. 28) Limited / M/s Diclofenac Tablet Bromelain 90mg, Sun (Volitra Enzo) R u toside Trihydrate Pharmaceuticals Industries BP 100mg Diclofenac Limited Sodium IP 50mg 9. Paracetamol + Each Uncoated tablet 1 Tablet 1.78 31015/19/2018- 544(E) dated M/s Akums Dicyclomine Tablet contains: Pricing dated 06.02.2018 Drugs and (Pacimol Spas) Paracetamol IP 22.6.2018 (at Sl. No. 1) Pharmaceutical 500mg, Ltd. / M/s IPCA Laboratories Ltd. Dicyclomine Hydrochloride IP 20 mg 10. Paracetamol + Each film coated 1 Tablet 2.36 31015/19/2018- 544(E) dated M/s IPCA Caffeine Tablate Tablet contains: Pricing dated 06.02.2018 Laboratories Ltd. (Pacimol Active) Paracetamol IP 22.6.2018 (at Sl. No. 6) 650mg, Caffeine Anhydrous IP 50mg26 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 11. Telmisartan + Each film coated 1 Tablet 9.00 31015/22/2018- 544(E) dated M/s Sun Pharma Amlodipine + tablet contains: Pricing dated 06.02.2018 Laboratories Chlorthalidone Telmisartan IP 40mg, 26.6.2018 (at Sl. No. 17) Limited Tablet Amlodipine Besylate (Tigatel ACH 40) IP eq. to Amlodipine 5mg, Chlorthalidone IP 12.5mg Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. [PN/191/59/2017/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director vkns’k ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3985¼v½.—tcfd vkS”k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½ vkns’k] 2013 ds iSjk 19 ds varxZr jlk;u ,oa moZjd ea=ky; }kjk tkjh dk0 vk0 3091¼v½ fnukad 20-09-2017 ds rgr ,vkbZvkslhMh&,MCY;w,lh,l dh QkesZfVd fjiksVZ esa lqlaxr foi.ku vk/kkfjr vkdM+ksa dh vuqifLFkfr esa ljdkjh [kjhn ,tsafl;ksa dh [kjhn dherksa ds vk/kkj ij ¼i½ Qsjl lkYV¼,½ $ Qksfyd ,flM¼ch½& 45 fexzk-¼,½ $ 400 ,elhth¼ch½ ¼ii½ Qsjl lkYV¼,½ $ Qksfyd ,flM¼ch½ &20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- dh vf/kdre dher fu;r dh gSA dk0 vk0 1461¼v½ fnukad 02-04-2018 ds rgr vf/kdre ewY; dks MCY;wihvkbZ ds vk/kkj ij ifj’kksf/kr fd;k x;kA 02- tcfd dqN fuekZrkvksa us ,uihih, ls vf/kdre dherksa iqujh{k.k gsrq vuqjks/k fd;k gS %& ¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM xksyh vkSj ¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk-¼,½ $ 400 ,elhth¼ch½ xksyh¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 27 ;g crk;k x;k gS fd ,uihih, }kjk fu;r ewY; vO;ogk;Z gSA fuekZrkvksa us ;g Hkh nkok fd;k gS fd vkiwfrZ eq[;r% ,uvkj,p,e ds fy, gSA 03- tcfd] ,uihih, dh 191 oha izkf/kdj.k dh cSBd tks fd 08-08-2018 dks vk;ksftr gqbZ Fkh ftlesa fofHkUu fuekZrkvksaa ds ;kfpdkvksa vkSj f’kdk;krksa ds vk/kkj ij vkS”k/k ¼ewY; fu;a=.k½ vkns’k] 2013 ds iSjk 19 ds rgr vf/kdre ewY;@ifj’kksf/kr ewY; dks okil ysus dk fu.kZ; fy;k gSA ¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk-¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM xksyh vkSj ¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk-¼,½ $ 400 ,elhth¼ch½ xksyh 07- vc] Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 19 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] vf/klwpuk la[;k dk-vk- 1461¼v½ fnukad 02-04-2018 vkSj dk-vk- 3091¼v½ fnukad 20-09-2017 dks bl vf/klwpuk dh frfFk ls fuEufyf[kr lhek rd vkS”kf/k dh vf/kdre ewY; dks okil ysrh Gsa Ø- fofufeZfr la- ¼i½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 20 fexzk- ,yhesaVy vk;ju ¼,½ $ 100,elhth¼ch½@fefy- vksjy fyD;wbZM ¼ii½ Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ & 45 fexzk- ,yhesaVy vk;ju ¼,½ $ 400 ,elhth¼ch½ xksyh vU; lHkh vf/kdre dhersa vkSj uksV izpkyu esa jgsaxs tc rd fo’ks”k :i ls la’kksf/kr@ifj’kksf/kr u gksA [dka- la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 13th August, 2018 S.O. 3985(E).—Whereas the National Pharmaceutical Pricing Authority(NPPA), Department of Pharmaceuticals, Ministry of Chemical and Fertilizers has fixed the ceiling price under paragraph 19 of the Drug (Prices Control) order 2013, of (i) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400 mcg(B) Tablet and (ii) Ferrous Salt (A) + Folic acid (B) – 20 mg(A) + 100mcg(B)/ml vide notification number SO 3091(E) dated 20.09.2017 based on the procurement prices of Government procurement agencies, in the absence of the relevant market based data in the Pharmatrac report of AIOCD-AWACS. Further, the ceiling prices were revised on the basis of WPI vide SO 1461(E) dated 2.4.2018. 02. Whereas some manufacturers have prayed to the NPPA for revisiting the ceiling prices of (i) Ferrous Salt (A) + Folic acid (B) – 20 mg(A) + 100mcg(B)/ml Oral Liquid and (ii) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400mcg(B) Tablet as the price fixed by the NPPA are unviable. The manufacturers also claimed that the supply is mainly for NRHM. 06. Whereas the NPPA in its 191st Authority meeting held on 08-08-2018, decided that ceiling price may be fixed/revised under para 19 of the DPCO 2013 considering the petition and grievances of various manufacturers decided to withdraw the notification in respect of (i) Ferrous Salt (A) + Folic acid (B) – 20 mg(A) + 100mcg(B)/ml Oral Liquid and (ii) Ferrous Salt (A) + Folic acid (B) – 45 mg(A) + 400mcg(B) Tablet 07. Now, in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby withdraw the ceiling price notification number SO 1461(E) dated 2nd April 2018 and SO 3091(E) dated 20.09.2017, with effect from the date of this notification, to the extent it belong to following scheduled formulation.28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. No. Scheduled Formulation (i) Ferrous Salt (A) + Folic acid (B) – 20 mg elemental iron (A) + 100mcg(B)/ml Oral Liquid (ii) Ferrous Salt (A) + Folic acid (B) – 45 mg elemental iron (A) + 400mcg(B) Tablet All the other ceiling prices and notes shall continue to be operation unless specifically amended/revised. [PN/191/59/2018/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director vkns’k ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3986¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr fofufnZ”V vkns’kksa la- 31015@3@2018 ewY; fu/kkZj.k fnukad 29-05-2016 ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 5, 11, vkSj 15 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) dk0 vk0 3947¼v½ lg ifBr ‘kqf) i= dk0 vk0 4041¼v½ rkjh[k 22-12-2017 dks ml lhek dh fofufeZfr;ksa rd jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ [kqnjk dher ds vf/kdre ewY; dks okfil ysrh gS] ¼i½ esVQkWfeZu 500 xzke] fXyesfijkbM 1 fexzk- vkSj fivksfXyVktksu 15 fexzk- xksyh vkSj ¼ii½ esVQkWfeZu 500 xzke] fXyesfijkbM 2 fexzk- vkSj fivksfXyVktksu 15 fexzk- xksyh dk0 vk0 3947¼v½ lg ifBr ‘kqf) i= dk0 vk0 4041¼v½ rkjh[k 22-12-2017 Øe la[;k 14 vkSj 15 esa fofufnZ”V eSllZ ;wuhlu QkekZL;wfVdYl izk- fy- }kjk foi.ku ,oa fofufeZr [kqnjk dherksa dks okil ysrh gSA dk0 vk0 3947¼v½ fnukad 20-12-2017 esa n’kkZbZ xbZ lHkh [kqnjk dhersa vkSj uksV izpkyu esa jgsaxs] tc rd fd fo’ks”k :i ls la’kksf/kr@ifj’kksf/kr u fd;k tk,A [dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 13th August, 2018 S.O. 3986(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) number 31015/3/2018-pricing dated 29.5.2018 passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) SO 3947(E) read with corrigendum SO 4041(E) dated 22.12.2017 to the extend it belong to the formulation specified hereafter, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby withdraw the fixation of retail price of (i) Metformin 500mg, Glimepiride 1mg & Pioglitazone 15mg Tablet and (ii) Metformin 500mg, Glimepiride 2mg & Pioglitazone 15mg Tablet specified at serial number 14 and 15 of the SO 3947(E) read with corrigendum SO 4041(E) dated 22.12.2017 marketed and manufactured by the M/s Unison Pharmaceuticals Pvt. Ltd. All the other retail prices specified in the SO 3947(E) dated 20.12.2017 and notes shall continue to be operation unless specifically amended/revised. [PN/191/59/2018/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 29 vkns’k ub Z fnYyh] 13 vxLr] 2018 dk-vk- 3987¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lg ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 19 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] us dk0 vk0 2668¼v½ rkjh[k 16 vxLr] 2017 }kjk tkjh vkFkksZisfMd ?kqVuk bEIykaVl ds fy, fu/kkZfjr vf/kdre dherksa dh iz;ksT;rk dks vxys ,d o”kZ dh vof/k ¼;kfu 15 vxLr] 2019 rd½ c<+kus dk fu.kZ; fy;k gS tc rd fd vU; jkti= vf/klwpuk }kjk la’kksf/kr u fd;k tk,A [dka-la-@191@59/2018@,Q@Qk- la0 8¼59½@2018@Mhih@,uihih,&fMoh--II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 13th August, 2018 S.O. 3987(E).—In exercise of the powers conferred by paragraph 19 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby decided that applicability of the ceiling prices fixed for orthopaedic knee implants vide SO 2668(E) dated 16 Aug, 2017 shall be extended for a period of another one year (i.e upto 15 Aug, 2019), unless revised by another gazette notification. [PN/191/59/2018/F/F. No. 8(59)/2018/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.